By comparing the prevalence of occult tumors at each stage to the incidence of serous ovarian cancer in a matched population of women (BRCA1 carriers, similar age), we estimated that serous tumors spend approximately 4.3 y as histopathologically detectable but clinically occult early stage tumors. Here, BRCA1 is linked to ovarian serous adenocarcinoma.